Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome

NCT04965636 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04965636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04965636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
July 14, 2022
Completion date
October 28, 2025
Enrollment
16 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

hypereosinophilic syndrome